Alimta

(Pemetrexed)

ApprovedSmall molecule

Pemetrexed is used to treat certain types of cancer, including lung cancer and mesothelioma (a cancer caused by asbestos exposure). It works by stopping cancer cells from growing and dividing.[2] Alimta is currently approved and in use across 85 indications[4].[1]

Alimta is one of 1082 small molecule programs targeting Central Nervous System Lymphoma. It is currently in Approved.

Indications

716

Total Trials

Active Trials

1,081

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Central Nervous System LymphomaRecruiting

Advanced Solid TumorsRecruiting

Non-Small Cell Lung Cancer (NSCLC)Suspended

CancerCompleted

EfficacyCompleted

Non-Squamous NSCLCCompleted

Selected Advanced Solid TumorsCompleted

KRAS P.G12CRecruiting

Thyroid CancerApproved

Rectum CancerApproved

Central Nervous System LymphomaPhase 2

Recruiting

Advanced Solid TumorsPhase 2

Recruiting

Non-Small Cell Lung Cancer (NSCLC)Preclinical

Suspended

CancerPhase 1

Completed

EfficacyPhase 3

Completed

Non-Squamous NSCLCPhase 3

Completed

Selected Advanced Solid TumorsPhase 1

Completed

KRAS P.G12CPreclinical

Recruiting

Thyroid CancerApproved

Approved

Rectum CancerApproved

Approved

Showing 10 of 85 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Alimta

SShawn Eagle

Approved

11 2

Zolymbus

AbbVie

Preclinical

1 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Duragesic-100

CCephalon

Preclinical

2 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 7

Spravato

WWim Janssens

Preclinical

2 8

Acupan

YYonsei University

Preclinical

1 9

Chantix

PPrism Pharmaceuticals

Preclinical

1 10

Nubain

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Phase II

NCT05870319

Q4 2026

Post-ApprovalActive, not recruiting

Lung Adenocarcinoma

NCT05689671

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT04129502

Phase 2Recruiting

Lung Cancer

NCT04966663

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT05104788

Phase 3Recruiting

Efficacy

NCT06754644

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer74 trials

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03950674·40 enrolled

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Completed· BeiGene logo

BeiGene·Phase 2·NCT05577702·121 enrolled

Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

Terminated·NNasser Hanna·Phase 2·NCT03713944·30 enrolled

Show 71 more trials

Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT06522360

A Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0801)

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT00886678·63 enrolled

NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer

Completed·AAGC Biologics S.p.A.·Phase 2·NCT00994097·121 enrolled

A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT01351415·485 enrolled

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Withdrawn· AbbVie logo

AbbVie·Phase 3·NCT06093503

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06417814·744 enrolled

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Unknown status·SShandong New Time Pharmaceutical Co., LTD·Phase 2·NCT05741021·84 enrolled

TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV

Withdrawn·AAktion Bronchialkarzinom e.V.·Phase 2·NCT01674738

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00982111·633 enrolled

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

Active, not recruiting·NNasser Hanna·Phase 2·NCT04367311·100 enrolled

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Terminated·—·Phase 1·NCT04173338·9 enrolled

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02535325·17 enrolled

A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]

Terminated·DDebiopharm International SA·Phase 1·NCT01714037·82 enrolled

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Terminated·NNewLink Genetics Corporation·Phase 2/3·NCT01774578·135 enrolled

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

Recruiting·QQian Chu·Phase 2·NCT06001151·49 enrolled

Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

Unknown status·TThe Netherlands Cancer Institute·Phase 3·NCT02743923·203 enrolled

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Completed·HHeat Biologics·Phase 1/2·NCT02439450·121 enrolled

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT03559049·25 enrolled

Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04453423·90 enrolled

A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer

Completed·OOncoMed Pharmaceuticals, Inc.·Phase 2·NCT02259582·82 enrolled

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Active, not recruiting· Takeda logo

Takeda·Phase 3·NCT04129502·354 enrolled

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00179699·40 enrolled

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT05891080·124 enrolled

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Active, not recruiting·SSWOG Cancer Research Network·Phase 2/3·NCT05096663·82 enrolled

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT05766800·100 enrolled

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Not yet recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT07229339·16 enrolled

Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00923273·42 enrolled

Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00807573·44 enrolled

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00686959·598 enrolled

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT05104788·27 enrolled

Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01809210·55 enrolled

Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Completed·MMayo Clinic·Phase 2·NCT03132532·20 enrolled

A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00550173·247 enrolled

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00372788·88 enrolled

KN046 in Patients With Advanced Non-small Cell Lung Cancer

Terminated·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 2·NCT03838848·120 enrolled

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Completed· Roche logo

Roche·Phase 3·NCT02604342·119 enrolled

Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases

Terminated·—·Phase 3·NCT02162537·95 enrolled

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

Recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT06829459·350 enrolled

Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer

Withdrawn·EEmory University·Phase 2·NCT04262869

Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00402051·133 enrolled

A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00190840·186 enrolled

Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer

Terminated·WWashington University School of Medicine·Phase 1/2·NCT00921310·12 enrolled

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02578680·616 enrolled

LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients

Recruiting·UUniversity of Illinois at Chicago·N/A·NCT06576635·29 enrolled

Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06109402·160 enrolled

Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT00071136·48 enrolled

Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB

Unknown status·XXinjiang Medical University·Phase 3·NCT02001168·392 enrolled

An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed

Completed· Eli Lilly logo

Eli Lilly··NCT00497770·434 enrolled

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT06094296·1 enrolled

Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193414·72 enrolled

Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01443078·42 enrolled

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Unknown status·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2·NCT04638582·44 enrolled

A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00762034·939 enrolled

A Study of Advanced or Metastatic Non-small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00988858·55 enrolled

A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

Terminated·TTufts Medical Center·Phase 2·NCT04856176·5 enrolled

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02998528·505 enrolled

Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT00351039·8 enrolled

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Completed· AbbVie logo

AbbVie·Phase 3·NCT02264990·595 enrolled

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04025879·461 enrolled

Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical Trial

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00061451·48 enrolled

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

Terminated·AAkeso·Phase 3·NCT03866980·164 enrolled

A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01165021·19 enrolled

ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00745875·66 enrolled

Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer

Terminated· Pfizer logo

Pfizer·Phase 2·NCT00321308·36 enrolled

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT02367781·723 enrolled

Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00533429·40 enrolled

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 2·NCT04533451·101 enrolled

A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer

Completed· AbbVie logo

AbbVie·Phase 1/2·NCT00297089·165 enrolled

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Terminated· Roche logo

Roche·Phase 2·NCT04832854·50 enrolled

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02041533·541 enrolled

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT04716933·201 enrolled

Lung Cancer13 trials

Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo

Terminated· Eli Lilly logo

Eli Lilly·Phase 2·NCT00538681·35 enrolled

Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT01705184·120 enrolled

Using ctDNA to Determine Therapies for Lung Cancer

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT04966663·66 enrolled

Show 10 more trials

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT03944772·247 enrolled

TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer

Terminated·—·Phase 3·NCT01282151·148 enrolled

Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00530621·160 enrolled

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Completed·SShanghai Junshi Bioscience Co., Ltd.·Phase 1/2·NCT05664971·119 enrolled

Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer

Terminated·SSCRI Development Innovations, LLC·Phase 2·NCT00402883·5 enrolled

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Active, not recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT05200481·110 enrolled

Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT05273814·30 enrolled

Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.

Terminated·HHikma Pharmaceuticals LLC·Phase 4·NCT03460678·9 enrolled

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Recruiting·VVanderbilt-Ingram Cancer Center·Phase 1/2·NCT05501665·25 enrolled

Maintaining ERBB Blockade in EGFR-mutated Lung Cancer

Terminated·AAIO-Studien-gGmbH·Phase 2·NCT02488694·4 enrolled

Small Cell Lung Cancer9 trials

Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer

Completed·—·Phase 1/2·NCT00216203·36 enrolled

Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)

Terminated· Eli Lilly logo

Eli Lilly·Phase 2·NCT00494026·4 enrolled

Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer

Terminated· Eli Lilly logo

Eli Lilly·Phase 2·NCT00259285·10 enrolled

Show 6 more trials

Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00363415·908 enrolled

Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer

Terminated· Eli Lilly logo

Eli Lilly·Phase 2·NCT00383331·19 enrolled

Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor

Terminated· Eli Lilly logo

Eli Lilly·Phase 2·NCT00356525·41 enrolled

A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01017874·236 enrolled

A Study in Non Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT01139775·76 enrolled

Clinical Study of Chinese Medicine Plus Chemotherapy Maintenance in Advanced Non Small Cell Lung Cancer

Completed·SShanghai University of Traditional Chinese Medicine·Phase 3·NCT02900742·71 enrolled

Breast Cancer6 trials

Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00149214·257 enrolled

Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00072865·50 enrolled

A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00034489

Show 3 more trials

A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00102219·77 enrolled

Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00065533·92 enrolled

A Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191347·30 enrolled

Non-squamous NSCLC5 trials

Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00769600·23 enrolled

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

Recruiting·FFudan University·Phase 2·NCT04136535·105 enrolled

Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC

Unknown status·GGuangdong Association of Clinical Trials·Phase 4·NCT03768037·106 enrolled

Show 2 more trials

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

Completed·CCanadian Cancer Trials Group·Phase 2·NCT02337530·62 enrolled

Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC

Terminated·CCheckpoint Therapeutics, Inc.·Phase 3·NCT04786964·25 enrolled

66 more indications

Chemotherapy5 trials

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Completed· Novartis logo

Novartis·Phase 3·NCT01828112·231 enrolled

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04530227·30 enrolled

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

Completed·MMassachusetts General Hospital·Phase 2·NCT03256136·9 enrolled

Show 2 more trials

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Withdrawn·SShirish M Gadgeel·Phase 2·NCT04470674

Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

Unknown status·XXinqiao Hospital of Chongqing·Phase 3·NCT02579564·134 enrolled

Pembrolizumab3 trials

Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT03242915·33 enrolled

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Terminated· Sanofi logo

Sanofi·Phase 2·NCT04524689·57 enrolled

Genetic Predictors of Benefit to Pembrolizumab

Terminated·—·Phase 2·NCT02710396·19 enrolled

Advanced NSCLC3 trials

Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00824408·143 enrolled

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT03987867·30 enrolled

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

Recruiting·HHackensack Meridian Health·Phase 2·NCT05715229·108 enrolled

Efficacy3 trials

A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC

Terminated·BBio-Thera Solutions·Phase 3·NCT06280196·162 enrolled

Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients

Completed· Sanofi logo

Sanofi·Phase 3·NCT00418886·698 enrolled

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT06754644·808 enrolled

Malignant Pleural Mesothelioma3 trials

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Completed·CCanadian Cancer Trials Group·Phase 2/3·NCT02784171·520 enrolled

Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)

Completed·NNovoCure GmbH·Phase 2·NCT02397928·82 enrolled

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

Completed·SSumitomo Pharma Co., Ltd.·Phase 1/2·NCT02347917·28 enrolled

Carboplatin3 trials

Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin

Withdrawn·QQueen Mary University of London·Phase 1·NCT03498222

Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC

Unknown status·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT00786331·230 enrolled

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Unknown status·SSamsung Medical Center·Phase 3·NCT03991403·228 enrolled

Efficacy and Safety3 trials

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Terminated· Novartis logo

Novartis·Phase 3·NCT03631199·673 enrolled

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07365410·60 enrolled

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT03607539·397 enrolled

Gastric Cancer2 trials

Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

Withdrawn·WWashington University School of Medicine·Phase 2·NCT02296671

Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00415168·53 enrolled

Leptomeningeal Metastasis2 trials

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Recruiting·GGuangzhou Medical University·Phase 2·NCT06296745·36 enrolled

Diagnosis of Leptomeningeal Metastasis and the Monitoring of Intrathecal Chemotherapy Efficacy in NSCLC

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology··NCT06346977·60 enrolled

Brain Metastases2 trials

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Unknown status·GGuangdong Association of Clinical Trials·Phase 3·NCT04768075·200 enrolled

Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

Unknown status·JJin Hyoung Kang·Phase 2·NCT05477615·28 enrolled

Mesothelioma2 trials

A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00190762·240 enrolled

Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma

Terminated·UUniversity Health Network, Toronto·Phase 2·NCT00895648·6 enrolled

Lung Adenocarcinoma2 trials

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

Active, not recruiting·—·Phase 4·NCT05689671·136 enrolled

Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma

Unknown status·MMarina Garassino·Phase 2·NCT03709147·64 enrolled

Leptomeningeal Metastases2 trials

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

Completed·NNorthwestern University·Phase 1·NCT00424242·15 enrolled

Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases

Not yet recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT06861218·42 enrolled

Performance Status2 trials

Trial of Poor Performance Status Patients (ToPPS)

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00892710·172 enrolled

Performance Status During Treatment With Pemetrexed in Patients With NSCLC

Completed· Eli Lilly logo

Eli Lilly··NCT00540241·542 enrolled

Pleural Mesothelioma2 trials

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma

Completed·MMorphotek·Phase 2·NCT00738582·89 enrolled

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02899299·605 enrolled

Advanced Solid Tumors2 trials

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Terminated· Sanofi logo

Sanofi·Phase 1/2·NCT04717375·125 enrolled

A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT05017012·72 enrolled

Trial2 trials

A Trial for Patients With Gestational Trophoblastic Disease

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00190918·50 enrolled

CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]

Completed·AAetion, Inc.··NCT06585189·304 enrolled

First-line Treatment2 trials

A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT07178795·440 enrolled

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00456261·110 enrolled

Cytoreductive Surgery1 trial

Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM

Terminated·—·Phase 1·NCT02838745·7 enrolled

Metastatic Cancer1 trial

A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191412·41 enrolled

Locally Advanced or Metastatic NSCLC1 trial

Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00061464·48 enrolled

Endometrial Cancer1 trial

A Trial for Patients With Advanced/Recurrent Endometrial Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00377520·27 enrolled

Glioma1 trial

Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific T Cells in the Treatment of Glioma and in Combination With Pemetrexed in the Treatment of Brain/Meningeal Metastases

Unknown status·SShanghai Pudong Hospital·Phase 1·NCT05459441·30 enrolled

Soft Tissue Sarcoma1 trial

Pemetrexed in Patients With Soft Tissue Sarcoma

Completed·UUniversity Hospital Tuebingen·Phase 2·NCT00427466·54 enrolled

Metastatic Solid Tumors1 trial

C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01296568·3 enrolled

Papilloma1 trial

A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy

Withdrawn·AAdvaxis, Inc.·Phase 2·NCT02531854

Phase II1 trial

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT05870319·376 enrolled

Metastatic Head and Neck Cancer1 trial

A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT02013453

Bladder Cancer1 trial

Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT00101842·61 enrolled

Biomarker1 trial

Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)

Terminated·UUniversität Duisburg-Essen·Phase 2·NCT02595840·4 enrolled

Urothelial Cancer1 trial

Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT00374868·59 enrolled

Urothelial Carcinoma1 trial

Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma

Completed·—·Phase 2·NCT01490437·42 enrolled

Cervical Cancer1 trial

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Withdrawn·AAgenus Inc.·Phase 3·NCT04943627

NSCLC1 trial

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00806819·718 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

Terminated·NNektar Therapeutics·Phase 1/2·NCT03138889·162 enrolled

Advanced Head and Neck Cancer1 trial

Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer

Terminated·FFox Chase Cancer Center·Phase 2·NCT00394147·17 enrolled

Pancreatic Cancer1 trial

Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00490373·52 enrolled

Neoadjuvant Immunotherapy1 trial

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT05800340·30 enrolled

Metastatic Colorectal Cancer1 trial

Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

Terminated·VVejle Hospital·Phase 2·NCT01109615·40 enrolled

Recurrent or Metastatic1 trial

A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01087970·69 enrolled

Growth1 trial

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

Completed· GSK logo

GSK·Phase 1·NCT01868022·65 enrolled

Immune Checkpoint Inhibitor1 trial

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Terminated·OOSE Immunotherapeutics·Phase 3·NCT02654587·219 enrolled

Patients With Advanced Solid Tumors1 trial

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03509012·105 enrolled

Carcinoma1 trial

A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma

Terminated· Regeneron logo

Regeneron·Phase 1/2·NCT00794417·60 enrolled

PD-L1 Positive1 trial

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

Active, not recruiting·EEffector Therapeutics·Phase 2·NCT04622007·68 enrolled

Intraperitoneal1 trial

Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 3·NCT03061058·240 enrolled

Resectable NSCLC1 trial

Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.

Withdrawn·SSun Yat-sen University·Phase 2·NCT03623776

PDL-11 trial

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT06364917·24 enrolled

Head and Neck Squamous Cell Cancer1 trial

Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00507858·36 enrolled

Impaired Renal Function1 trial

Pemetrexed in Maintenance in Patients With Impaired Renal Function, 2 Dose Calculation Strategies

Completed·CCentre Georges Francois Leclerc·Phase 4·NCT03607149·11 enrolled

EGFR Mutation1 trial

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Terminated· Novartis logo

Novartis·Phase 2·NCT01646125·59 enrolled

Neuroendocrine Tumors1 trial

Pemetrexed in Patients With Advanced Neuroendocrine Tumors

Completed·—·Phase 2·NCT00424723·32 enrolled

Head and Neck Cancer1 trial

Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer

Completed·UUniversity of Pittsburgh·Phase 1·NCT00291707·40 enrolled

Blood Pressure Monitoring1 trial

Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC

Completed·UUniversity of Chicago·N/A·NCT01063283·20 enrolled

Advanced or Metastatic Solid Tumors1 trial

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Completed· Incyte logo

Incyte·Phase 1/2·NCT03085914·70 enrolled

ESS1 trial

Alvopem® (Pemetrexed) Safety Assessment

Completed·NNanoAlvand··NCT04843007·199 enrolled

Metastatic NSCLC1 trial

Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC

Completed·CCanadian Cancer Trials Group·Phase 1·NCT01783197·39 enrolled

Advanced Cancer1 trial

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02124148·167 enrolled

Interaction1 trial

A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01358968·20 enrolled

Mycosis Fungoides1 trial

Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome

Terminated·NNorthwestern University·Phase 1·NCT00369629·14 enrolled

Cancer1 trial

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT03819465·175 enrolled

Recurrent NSCLC1 trial

Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00612677·1 enrolled

Gefitinib1 trial

Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

Completed·GGachon University Gil Medical Center·Phase 2·NCT01783834·95 enrolled

IMT1 trial

ZD6474(Vandetanib) + Alimta Combo Study

Completed· Sanofi logo

Sanofi·Phase 1·NCT00506051·21 enrolled

Ovarian Cancer1 trial

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Completed·EEpicentRx, Inc.·Phase 2·NCT02489903·139 enrolled

Unspecified1 trial

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT00733031·75 enrolled

Regulatory

FDA Approval Timeline[5]

Feb 4, 2004

ALIMTA

NDA NDA021462

Jul 28, 2006

ALIMTA

NDA NDA021462

Feb 2, 2007

ALIMTA

NDA NDA021462

Sep 7, 2007

ALIMTA

NDA NDA021462

Sep 7, 2007

ALIMTA

NDA NDA021462

Sep 26, 2008

ALIMTA

NDA NDA021462

Jul 2, 2009

ALIMTA

NDA NDA021462

Jul 2, 2009

ALIMTA

NDA NDA021462

Jul 2, 2009

ALIMTA

NDA NDA021462

Mar 17, 2011

ALIMTA

NDA NDA021462

Nov 18, 2011

ALIMTA

NDA NDA021462

Nov 18, 2011

ALIMTA

NDA NDA021462

Nov 18, 2011

ALIMTA

NDA NDA021462

Jun 4, 2012

ALIMTA

NDA NDA021462

Oct 17, 2012

ALIMTA

NDA NDA021462

Nov 9, 2012

ALIMTA

NDA NDA021462

Jan 18, 2013

ALIMTA

NDA NDA021462

Mar 13, 2013

ALIMTA

NDA NDA021462

Sep 12, 2013

ALIMTA

NDA NDA021462

Aug 11, 2014

ALIMTA

NDA NDA021462

Jan 8, 2016

ALIMTA

NDA NDA021462

Oct 11, 2017

ALIMTA

NDA NDA021462

Apr 17, 2018

ALIMTA

NDA NDA021462

Jun 4, 2018

ALIMTA

NDA NDA021462

Jan 30, 2019

ALIMTA

NDA NDA021462

Feb 8, 2020

PEMFEXY

NDA NDA209472

Aug 21, 2020

PEMETREXED

NDA NDA208419

May 26, 2022

PEMETREXED DISODIUM

NDA NDA214657

Jun 22, 2022

PEMETREXED DISODIUM

NDA NDA214218

Jul 19, 2022

PEMETREXED DISODIUM

NDA NDA214408

Aug 31, 2022

ALIMTA

NDA NDA021462

May 22, 2023

PEMETREXED

NDA NDA215179

Sources

References

[1]
ClinicalTrials.gov — 716 trial records for Pemetrexed. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Alimta drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Pemetrexed compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Pemetrexed. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA215179). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Alimta. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Shawn Eagle company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Dihydrofolate Reductase Inhibitor; GAR Transformylase Inhibitor; Thymidylate Synthase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: SShawn Eagle

Patent Landscape[6]

Patent Cliff

Mar 26, 2035

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11147817Mar 26, 2035

9604990Oct 28, 2035

12115164Feb 19, 2036

11793813Feb 19, 2036